INO analyst estimates
Inovio (INO) analyst ratings, the average price target and its range, and every firm's latest call.
INO analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 13, 2026 | Jefferies | Inovio upgraded to Buy from Hold at Jefferies | $3.00 |
| Jun 1, 2026 | H.C. Wainwright | Inovio price target lowered to $2.50 from $3 at H.C. Wainwright | $2.50 |
| Nov 14, 2025 | Piper Sandler | 'Inovio Pharmaceuticals (INO) Raises $28.75M to Fund Operations'; PT Raised at Piper Sandler | $6.00 |
| Aug 9, 2024 | RBC Capital | Inovio Pharmaceuticals (INO) PT Lowered to $8 at RBC Capital | $8.00 |
| May 14, 2024 | Oppenheimer | Oppenheimer Reiterates Outperform Rating on Inovio Pharmaceuticals (INO) | $40.00 |
| May 13, 2024 | Stephens | Inovio initiated with an Overweight at Stephens | $20.00 |
| Jan 25, 2024 | Oppenheimer | Oppenheimer Upgrades Inovio Pharmaceuticals (INO) to Outperform | $4.00 |
- 3 firms rate INO: 2 buy, 1 hold, 0 sell.
- The average price target is $2.75 from 2 analysts, from $2.50 to $3.00.
Updated 2026-11-02 17:51 UTC